ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.892,93
-0,27%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Elevation Oncology Inc (ELEV)

  7. Elevation Oncology Inc (ELEV) Notícias

ELEV

Elevation Oncology (ELEV)

Elevation Oncology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELEV
DataHoraFonteTítuloCódigoCompanhia
17/05/202417:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
10/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELEVElevation Oncology Inc
09/05/202417:39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELEVElevation Oncology Inc
07/05/202408:30PR Newswire (US)Elevation Oncology to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ELEVElevation Oncology Inc
02/05/202408:30PR Newswire (US)Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
08/04/202417:30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
06/03/202410:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELEVElevation Oncology Inc
06/03/202409:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
06/03/202409:30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/03/202409:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ELEVElevation Oncology Inc
05/03/202418:50PR Newswire (US)Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
04/03/202418:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
04/03/202409:30PR Newswire (US)Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
28/02/202409:30PR Newswire (US)Elevation Oncology to Participate in Upcoming Investor ConferencesNASDAQ:ELEVElevation Oncology Inc
22/02/202409:30PR Newswire (US)Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanNASDAQ:ELEVElevation Oncology Inc
14/02/202418:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
22/01/202418:57Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELEVElevation Oncology Inc
22/01/202409:30PR Newswire (US)Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
05/01/202409:30PR Newswire (US)Elevation Oncology Announces Program Updates and Upcoming 2024 MilestonesNASDAQ:ELEVElevation Oncology Inc
22/11/202309:30PR Newswire (US)Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:ELEVElevation Oncology Inc
02/11/202308:30PR Newswire (US)Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
02/11/202308:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELEVElevation Oncology Inc
05/09/202308:30PR Newswire (US)Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ELEVElevation Oncology Inc
16/08/202308:30PR Newswire (US)Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021NASDAQ:ELEVElevation Oncology Inc
03/08/202308:30PR Newswire (US)Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
03/08/202308:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELEVElevation Oncology Inc
13/07/202309:00PR Newswire (US)Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial OfficerNASDAQ:ELEVElevation Oncology Inc
21/06/202317:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ELEVElevation Oncology Inc
20/06/202317:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELEVElevation Oncology Inc
15/06/202317:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ELEVElevation Oncology Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ELEV

Seu Histórico Recente

COIN
CNEGBP
NYSE
KVU
Strd Pdt 8 Corts Frd
LSE
30OA
Westpac 25
LSE
45SI
Anz Bank 23
COIN
MFTUUST
MFTU
BIT
UC6GMV
Unicredit Bank
BIT
P14I75
BNP Paribas Issuance
BOV
TRPL4
ISA CTEEP PN
BIT
I07573
INTESA SANPAOLO
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados